AstraZeneca completes sale of US rights for nasal spray
AstraZeneca has completed the sale of rights to its nasal spray outside of the US with Swiss pharmaceutical Cilag for $330m.
AstraZeneca
11,526.00p
13:10 24/09/24
-0.50%
-58.00p
Dow Jones I.A.
42,124.65
04:30 15/10/20
n/a
n/a
FTSE 100
8,280.42
13:10 24/09/24
n/a
n/a
FTSE 350
4,567.37
13:10 24/09/24
n/a
n/a
FTSE All-Share
4,523.54
13:10 24/09/24
n/a
n/a
Johnson & Johnson
$163.22
11:09 23/09/24
-0.57%
-$0.94
Pharmaceuticals & Biotechnology
22,066.38
13:09 24/09/24
-0.49%
-108.43
The FTSE 100 company sold the rights for Rhinocort Aqua, a nasal spray to treat allergic and nonallergic rhinitis and polyps, for use outside of the US to a subsidiary of Johnson & Johnson.
It received payment of £330m, which will be booked in the fourth quarter of 2016, and will now not have a significant ongoing interest in Rhinocort Aqua.